Sentences with phrase «biotechnology company developing»

Gosselies, Belgium — June 29, 2017 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Dr. Mohamed Ragab, M.D., has been appointed as Vice President of Corporate Development.

Gosselies, Belgium — November 6, 2017 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the presentation of posters on its novel A2A receptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, taking place from November 8 - 12, 2017 in National Harbor, Maryland.

Gosselies, Belgium — January 4, 2017 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that it has regained exclusive worldwide rights from Pfizer to develop and commercialise EOS200271, a highly selective, clinical - stage IDO1 inhibitor.

Gosselies, Belgium — August 8, 2017 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that Michel Detheux, iTeos» Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 12:45 a.m. ET in New York, NY.

Dan also serves as Executive Chair of FluGen, Inc., a biotechnology company developing a novel, single round replicating influenza vaccine.

Gosselies, Belgium — February 9, 2018 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it will present new data for its A2A antagonist and anti-TIGIT antibody programs in two oral presentations at the upcoming Molecular Medicine Tri-Conference 2018, taking place from February 11 - 16, 2018 in San Francisco, CA.

Completes $ 55 Million Series C Financing March 19, 2018 SAN FRANCISCO, March 19, 2018 / PRNewswire / — UNITY Biotechnology, Inc. («UNITY»), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the closing of a $ 55 million Series C financing.

biotechnology company developing novel cancer immunotherapies, today announces that it will present new data for its A2A

Gosselies, Belgium — July 28, 2017 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it has been granted EUR 7.5 million in non-dilutive funding * to support the clinical development of its lead anti-cancer drug.

Gosselies, Belgium - April 3, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, will present preclinical data for its A2A receptor antagonist, which inhibits the immune suppressive function of adenosine, at the American Association for Cancer Research (AACR) Annual Meeting.

Cambridge, MA, September 07, 2016 — Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that it has initiated a Phase 1b clinical trial evaluating NPT088, its lead development candidate for Alzheimer's disease.

CAMBRIDGE, Mass., Mar. 1, 2017 — Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that Franz Hefti, Ph.D., president and chief executive officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 1:30 p.m. ET in Boston.

CAMBRIDGE, Mass., Nov. 16, 2016 — Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that the U.S. Patent and Trademark Office has issued two new patents related to the company's proprietary General Amyloid Interaction Motif (GAIM) platform.

To a job in a biotechnology company developing a cure for baldness.

«Cancer is like a person's thumbprint; each person's cancer is uniquely theirs,» says Bill Hearl, CEO of Immunomic Therapeutics, a clinical stage biotechnology company developing a nucleic acid immunotherapy platform with the potential to treat cancer, allergies and animal health issues.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

Cambridge, MA — December 21, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it closed a $ 30 million Series C financing.

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

• Myonexus Therapeutics, a New Albany, Oh. - based clinical - stage biotechnology company developing transformative gene therapies for limb - girdle muscular dystrophies, raised $ 2.5 million in seed funding.

Not exact matches

A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Eagle's Sassouni pointed out that since the big drug companies are losing billions of dollars every year to generic versions and have little to spend on their own research and development, they are looking to buy smaller biotechnology companies that are developing their own products.

• Exonics Therapeutics, Inc, a Boston - based biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, raised $ 40 million in Series A funding.

It is important to state that the Biotechnology industry does not include companies that are involved in developing small - molecule pharmaceuticals, performing contract research or manufacturing biological equipment.

This is a global biotechnology company that develops and manufactures a range of human therapeutics.

AMSTERDAM, NETHERLANDS — December 6, 2017 — Synaffix BV, a biotechnology company that has developed a proprietary site - specific conjugation platform technology to enable differentiated antibody - drug conjugates (ADCs), today announced the launch of a new platform of...

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

Many major pharmaceutical companies have stopped researching and developing new antibiotics altogether, shifting more of that responsibility to smaller, nimbler biotechnology startups.

Companies developing things that could benefit from experiments in microgravity, such as biotechnology and new materials, are not flying them currently because they would need to wait years and pay a high price to put them on the ISS, says Gold.

Researchers from the Singapore - MIT Alliance for Research and Technology (SMART), DukeNUS Graduate School of Medicine (Duke - NUS), National University of Singapore (NUS) and Nanyang Technological University (NTU) have collaborated with the Massachusetts Institute of Technology (MIT) and a biotechnology company, Visterra, to develop a single treatment.

A U.S. biotechnology company has found early success with a cancer drug developed by a supercomputer, BBC reports.

The Brain Trauma Indicator, developed by San Diego — based biotechnology company Banyan Biomarkers, was reviewed and authorized for commercialization in fewer than six months.

My qualitative postdoctoral research project is focusing on the role of private biotechnology companies in addressing local health needs in developing countries; it will involve travel to several countries, including China, India, Brazil, and South Africa.

Not for nothing are major agrochemicals and biotechnology companies investing heavily in developing such transgenic crops.

Biotechnology and drug companies are developing several different potential remedies.

The antibody - based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology company, is a simple, cost - effective way to determine if a person's infection is from the Zika virus or another virus of the same family, such as dengue and West Nile viruses.

The group's statement reassured biotechnology companies that their intellectual property rights would be respected and that «facilitating technology transfer» did not mean that they would have to give away patent licences to developing countries that provided them with the genetic resources for new drugs.

So to test the process in humans, HCI scientists worked with a biotechnology company that was developing a Ron inhibitor - an oral drug that blocks the activity of Ron.

A few programs serve science graduates who want to go into toxicology; UW, for example, just launched a certificate program in biologics safety to teach basic toxicology to scientists working at biotechnology companies that develop protein and other medicines based on large molecules.

A drug called PBT2, developed by Australian company Prana Biotechnology, appears to improve cognitive abilities in patients with early - stage Alzheimer's disease and reduce protein buildup blamed for the debilitating neurological disorder, researchers report in The Lancet Neurology.

A drug called PBT2, developed by Australian company Prana Biotechnology, appears to improve cognitive abilities in patients with early - stage Alzheimer's disease.

Rhône - Poulenc has joined forces with a Californian biotechnology company called Calgene in developing a genetically engineered cotton with built - in resistance to a herbicide called bromoxynil.

So far, Chien says, biotechnology companies have not been as vulnerable because their patents are not as broad as software patents, and require more time and expertise to develop.

As part of my new position, I was involved in developing partnerships with different biotechnology companies, and I started making new contacts.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs.

(b) The University of California is requested to utilize California's unique collaborative research environment by convening stakeholders from public and private research institutions, national laboratories, biotechnology and high technology companies, and venture capital firms to develop the governing structure for the Cal - BRAIN program.

We established formal partnerships with major pharmaceutical and biotechnology companies to develop compounds or identify targets that enhance interneuron function or restore brain rhythms in models of AD and epilepsy.

We are actively developing these systems through Lyndra, a biotechnology company we have started with Prof. Robert Langer to help bring these technologies to patients.»

Several biotechnology companies are using the gene editing technique in an effort to develop therapies for treating genetic diseases, including CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine.

They have joined forces with CHS Pharma, Inc., a South Florida - based biotechnology development company that has an intellectual property portfolio for potential treatments related to ischemic stroke, dry macular degeneration as well as other age - related disorders such as Alzheimer's disease, to further develop and commercialize this promising technology.

By partnering with companies in diverse application areas, Caribou is able to integrate discoveries from therapeutic research, agricultural biotechnology and industrial biotechnology to develop the platform further.